Efficacy of a psychotherapeutic group intervention for patients with Post-COVID-19 condition: A randomized controlled trial (PsyLoCo study)

Efficacy of a psychotherapeutic group intervention for patients with Post-COVID-19 condition: A randomized controlled trial (PsyLoCo study) - PsyLoCo

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00040598

Enrollment

Registered

2026-06-23

Start date

2024-02-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U09.9

Interventions

Group 1: Arm 1: Immediate Intervention Group Participants are randomized to the intervention group following baseline assessment and immediately receive the manualized group psychotherapeutic interve

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age = 18 years. 2. Previous SARS-CoV-2 infection. 3. Presence of at least one persistent symptom following SARS-CoV-2 infection. 4. Clinically relevant functional impairment due to the symptoms. 5. Ability to participate in a German-language group psychotherapy program. 6. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Acute psychotic disorder. 2. Bipolar disorder. 3. Severe substance use disorder. 4. Acute suicidality. 5. Current psychotherapy. 6. Insufficient German language proficiency.

Design outcomes

Primary

Measure	Time frame
Change in somatic symptom burden from baseline to post-treatment, measured using the Somatic Symptom Scale-8 (SSS-8).	—

Secondary

Measure	Time frame
1. Change in depressive symptom severity from baseline to post-treatment, measured using the Patient Health Questionnaire-9 (PHQ-9). 2. Change in anxiety symptom severity from baseline to post-treatment, measured using the Generalized Anxiety Disorder-7 (GAD-7). 3. Change in the severity of Post-COVID-19-related symptoms (e.g., fatigue, concentration difficulties, memory impairment, olfactory and gustatory disturbances). 4. Exploratory analysis of childhood maltreatment, assessed using the Childhood Trauma Screener (CTS), as a potential moderator of treatment response. 5. Exploratory investigation of baseline symptom severity as a predictor of treatment outcome.	—

Measure

Time frame

1. Change in depressive symptom severity from baseline to post-treatment, measured using the Patient Health Questionnaire-9 (PHQ-9). 2. Change in anxiety symptom severity from baseline to post-treatment, measured using the Generalized Anxiety Disorder-7 (GAD-7). 3. Change in the severity of Post-COVID-19-related symptoms (e.g., fatigue, concentration difficulties, memory impairment, olfactory and gustatory disturbances). 4. Exploratory analysis of childhood maltreatment, assessed using the Childhood Trauma Screener (CTS), as a potential moderator of treatment response. 5. Exploratory investigation of baseline symptom severity as a predictor of treatment outcome.

—

Countries

Germany

Contacts

Public ContactFlorian Junne

Universitätsmedizin Magdeburg

kpsm@med.ovgu.de+49391671400

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026